Sidney Spector, MD, PhD
Sidney Spector, MD, PhD is Senior Vice President of Global Strategy and Medical Affairs at Brainstorm. A physician and scientist, Sid has over twenty years of experience in the development of innovative medicines for neurological and psychiatric disorders, and he is currently Clinical Associate Professor of Neurology at the University of Arizona School of Medicine. Prior to joining Brainstorm, Sid was Vice President of US Medical Affairs at Avexis before its acquisition by Novartis, supporting clinical development and launch of Zolgenzma ®, a gene replacement therapy for spinal muscular atrophy, after which he continued at Novartis supporting these global efforts while assuming clinical lead responsible for management of Asia/Pacific clinical development and regulatory submissions. Earlier in his career, he held senior roles in CNS drug development and medical affairs at Elan Pharmaceuticals (Tysabri®, Prialt®) and Pfizer Inc. (Geodon®, Relpax®).
Dr. Spector earned his medical degree at the University of Tel Aviv Sackler School of Medicine, and his PhD in Kinesiological Sciences at the University of California, Los Angeles. He completed post-doctoral fellowships at the National Institutes of Health, NINCDS in Neuromuscular Diseases and Neurokinesiology.